Navigation Links
Leading pharmacologists to meet in Brighton

The latest developments in drug discovery including solutions to tackle obesity, the latest on the Northwick Park drug-trial disaster and issues surrounding drugs used in sport and the Olympics will be highlighted at a conference in Brighton next week.

The British Pharmacological Society (BPS), Europe's leading pharmacological research society, is to host its Winter Meeting in the seaside resort, attracting experts from across the world.

Running from 16 to 18 December, the three-day conference will hear the latest research tackling the global obesity problem.

Other researchers will present their work on the safety of drugs, particularly the new biopharmaceuticals developed in the wake of the Northwick Park drug-trial disaster in 2006 that left six volunteers fighting for their lives.

A third theme of the conference will examine the latest techniques using stem-cell therapies to tackle heart disease.

Just three presentations from the packed programme will be press released but newsworthy research to be presented at the Brighton conference includes:

  • Professor Luke O'Neill (Trinity College Dublin): 'The IL-1 receptor / Toll-like receptor super-family: 10 years of progress'
  • Professor O'Neill's talk will deal with possible new targets for drugs to treat immune and inflammatory diseases.
  • These targets are the Toll-like receptors (TLRs) and they have been identified as possible new targets to block in such diseases as rheumatoid arthritis, inflammatory bowel disease, atherosclerosis and multiple sclerosis.
  • They are also implicated in infectious diseases such as malaria and TB. TLRs have been shown to be over-active in these diseases - they go into overdrive and cause inflammation and damage.
  • There is a consensus emerging that inhibiting them might prove useful to treat these diseases, or, alternatively, if they are activated, they might boost the immune response to help generate new vaccines.
  • In his talk, Professor O'Neill will lay out the case for TLRs as excellent new targets worth exploring for these diseases where there remains a major unmet medical need.
  • He will also describe what to target his team has found proteins within the Toll-like receptor pathway that might lend themselves to therapeutic manipulation.
  • TLRs may also prove essential in the fight against malaria, as the disease has recently shown resistance to current medication (16 Dec).
  • Dr Sandra Diebold (Cancer Research UK): 'Stimulatory nucleic acids as adjuvants for tumour immunotherapty' (16 Dec)
  • Dr Stephen Poole (National Institute for Biological Standards and Controls): 'Cytokine Storm in the phase 1 trial of monoclonal antibody TGN1412 better understanding the causes to improve preclinical testing of immunotherapeutics' (16 Dec)
  • Dr Ben Field (Imperial College, London): 'New targets peripheral obesity' (17 Dec)
  • Dr Nick Finer (Wellcome Clinical Research Facility, Cambridge): 'Clinical challenges: can current drugs compete with surgery?' (17 Dec)
  • Dr Christine Mummery (Leiden University Medical Centre, Netherlands): 'Cardiomyocytes from human embryonic stem cells: towards cell-based therapy and disease models' (18 Dec)
  • Dr Marisa Jaconi (Geneva University, Switzerland): ' Tissue-engineered strategies using biomatrices to implant stem cells into the infarcted heart' (18 Dec)
  • Dr Kai C. Wollert (Hanover Medical School, Germany): 'Bone marrow cell therapy after myocardial infarction: the BOOST experience' (18 Dec)


Contact: Aeron Haworth
University of Manchester

Related medicine news :

1. Cancer to Surpass Heart Disease as Worlds Leading Killer
2. Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden
3. Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications
4. Misleading media coverage of medicine
5. Leading German Health Insurance Organization, Deutsche Angestellten-Krankenkasse (DAK), Standardizes on Jive Software to Harness Employee Knowledge
6. Tigermed Forms Strategic Partnerships With Leading CROs in Russia and South Korea
7. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
8. Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign
9. Leading Healthcare Provider Signs Agreement With UCN for inContact
10. Leading Scientists From Around the World Headed to Kansas for Symposium on Combating Deadly Infectious Diseases
11. and Alzheimer's Association Use Social Media to Help Spread Awareness for the Nation's Sixth Leading Cause of Death
Post Your Comments:
(Date:11/25/2015)... ... ... Dr. John Pierce, Medical Director at the Ageless Forever clinic in Las ... Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 offers men ... surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a home-use device ...
(Date:11/25/2015)... ... 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed a class ... of a home health care worker who provided companionship services for the elderly, ill ... employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article ... being more and more widely heralded as a breakthrough for performing hernia repairs. The ... over traditional laparoscopic surgery is that it can greatly reduce the pain that a ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to ... are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses ... , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon ... programs, launches new Wimbledon Athletics Facebook page to educate the public, ... unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die from ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Advanced Wound Care Market by Type (Dressings, ... End User (In-Patient Facility, Out-Patient Facility), and Geography - ... --> --> ... description, definition and forecast of the global advanced wound ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology: